ProCE Banner Activity

Using Biomarkers to Guide NSCLC Care: An Expert Discussion

Clinical Thought
Three experts review current molecular testing in NSCLC and discuss how they apply biomarkers to guide care of patients with targeted agents in real-world clinical practice.

Released: May 26, 2022

Expiration: May 25, 2023

Share

Faculty

Todd M. Bauer

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Sandip P. Patel

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Joshua Sabari

Joshua Sabari, MD

Assistant Professor of Medicine
Thoracic Medical Oncology
Phase I Experimental Therapeutics
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lilly

Novartis Pharmaceuticals Corporation

Turning Point Therapeutics Inc

Faculty Disclosure

Primary Author

Todd M. Bauer, MD

Senior Investigator, Greco-Hainsworth Centers for Research
Tennessee Oncology, PLLC
Nashville, Tennessee

Todd M. Bauer, MD: research support (paid to institution): AbbVie, Aileron, Amgen, ARMO Biosciences, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Calithera, Clovis, Daiichi Sankyo, Deciphera, Five Prime, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Ignyta, Immunocore, Immunogen, Incyte, Jacobio, Janssen, Karyopharm, Kolltan, Leap, Lilly, Loxo, MabVax, MedImmune, Medpacto, Merck, Merrimack, Millennium, Mirati, Moderna, Novartis, Onyx, Pfizer, Peleton, Phosplatin Therapeutics, Principa Biopharma, Roche, Sanofi, Stemline, Takeda, Top Alliance BioScience; consultant/advisor/speaker: Bayer, Blueprint Medicines, Exelixis, Ignyta, Guardant Health, Loxo, Moderna, Pfizer; fees for non-CME/CE services: Astellas, AstraZeneca, Celgene, Clovis Oncology, EMD Serono, Genentech, Lilly, Merck, Novartis, Pharmacyclics, Pfizer, Sysmex.

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Sandip P. Patel, MD: research support: Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Fate Therapeutics, Iovance, Lilly, Merck, Pfizer, Roche/Genentech, SQZ Biotechnologies; consultant/advisor/speaker: Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Genentech, Illumina, Lilly, Merck, Pfizer, Rakuten, Tempus.

Joshua Sabari, MD

Assistant Professor of Medicine
Thoracic Medical Oncology
Phase I Experimental Therapeutics
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Joshua Sabari, MD: consultant/advisor/speaker: AstraZeneca, Genentech, Janssen, Mirati, Navire, Pfizer, Regeneron, Sanofi Genzyme, Takeda.